### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)



## (19) World Intellectual Property Organization International Bureau



## (43) International Publication Date 12 July 2001 (12.07.2001)

PCT

## (10) International Publication Number WO 01/49669 A1

- (51) International Patent Classification?: C07D 253/07
- (21) International Application Number: PCT/IN00/00001
- (22) International Filing Date: 3 January 2000 (03.01,2000)
- (25) Filing Language:

English

(26) Publication Language:

English

- (71) Applicant (for all designated States except US): RPG LIFE SCIENCES LIMITED [IN/IN]; 21, D Sukhadvala, Mumbai 400 001, Maharashtra (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): RADHAKRISH-NAN, Tarur, Venkatasubramanian [IN/IN]; RPG Life Sciences Limited. 25 MIDC Land. Thane-Belapur Road, Navi-Mumbai 400 705. Maharashtra (IN). SASIKUMAR, Thoovara, Mohan [IN/IN]; RPG Life Sciences Limited. 25 MIDC Land, Thane-Belapur Road. Navi-Mumbai 400 705. Maharashtra (IN). SRIVASTAVA, Anita, Ranjan [IN/IN]; RPG Life Sciences Limited. 25 MIDC Land, Thane-Belapur Road, Navi-Mumbai 400 705. Maharashtra (IN).


- (74) Agents: DEPENNING, Robert, G. et al.; Depenning & Depenning, Alaknanda, 16 Nepean Sea Road, Mumbai 400 036 (IN).
- (81) Designated States (national): AE. AL, AM. AT, AU. AZ. BA. BB. BG. BR. BY. CA. CH. CN. CR. CU. CZ. DE. DK. DM. EE. ES. FI. GB. GD. GE. GH. GM. HR. HU, ID. IL. IN. IS. JP. KE. KG. KP. KR. KZ. LC. LK. LR. LS. LT. LU. LV. MA. MD. MG. MK. MN. MW. MX. NO. NZ. PL. PT. RO. RU, SD. SE. SG. SI. SK. SL. TJ. TM. TR. TT. TZ. UA. UG. US. UZ. VN. YU. ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, Fl, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, Cl, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


#### Published:

-- With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A PROCESS FOR THE PREPARATION OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE-3,5-DIAMINE. COM-MONLY KNOWN AS LAMOTRIGINE





(57) Abstract: A process for the preparation of 6-(2,3dichlorophenyl)-1,2,4-triazine-3-5-diamine (lamotrigine) formula (I). 2.3-Dichloronitrobenzene in C<sub>1</sub>-C<sub>6</sub> aliphatic alkanol is hydrogenated at 55-90 psi gas pressure using metal catalyst at 27-35 °C. 2,3-Dichloroaniline is diazotised and cyano-de-diazonised with metal cyanide at 65-80 °C. 2,3-Dichlorobenzonitrile is hydrolysed and 2,3-dichlorobenzoic acid is chlorinated at 55-130 °C. Cyano-de-halogenation of 2,3-dichlorobenzoyl chloride is carried out with a metal cyanide and alkali metal iodide by refluxing in an aprotic solvent under an inert atmosphere. 2,3-Dichlorobenzoyl cyanide is condensed with aminoguanidine bicarbonate in an organic solvent in acidic conditions using catalyst at 90-125 °C followed by in situ cyclisation of the Schiff's base by refluxing in an aliphatic alkanol with base. Crude lamotrigine is purified.

WO 01/49669 PCT/IN00/00001

### TITLE OF INVENTION

A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine.

### Technical Field

5

10

15

20

This invention relates to a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I:

Formula I

commonly known as Lamotrigine.

Lamotrigine, an anti-epileptic drug, elicits its action by suppressing seizures by inhibiting the release of excitatory neurotransmitters. Lamotrigine presently offers a worthwhile alternative for treating patients suffering from nitractable partial seizures coupled with or without secondary generalised seizures and therefore shows good potential for broader applications in other areas of epilepsy management.

10

15

20

25

### **Background Art**

One method of preparation of lamotrigine of the formula I involves reaction of 6-(2,3-dichlorophenyl)-5-chloro-3-thiomethyl-1,2,4-triazine of the formula II:

#### Formula II

with ethanolic ammonia in a sealed tube at 180°C/250 psi pressure (PCT Publication No WO 96/20935). This process is time consuming (~ 72 hours) and also produces lamotrigine in low yields because of which it is not commercially viable.

Another route for the synthesis of lamotrigine of the formula I involves photochemical reaction of the compound of the formula III:

$$C = N - N = C = NH_2$$

$$R$$

$$NH_2$$

Formula III

where R = CN or  $CONH_2$ , using ultraviolet or visible radiation in the presence of a base in an alkanol solvent and also heating when R = CN (PCT Publication No WO 96/20934). The preparation of the compound

10

15

20

25

of the formula III involves expensive and hazardous reagents. Further, undesired by-products like the de-aminated hydroxy derivative of triazine formed during the photochemical reaction demand elaborate separation and purification techniques, thereby making this route lengthy and tedious, besides producing low yields of lamotrigine (< 10 %). Therefore this process is not suitable for industrial scale manufacture of lamotrigine.

Yet another method for the synthesis of lamotrigine of the formula I involves cyclisation of the Schiff's base of the formula IV:

$$CI \qquad CI \qquad CI \qquad N - N - C \qquad NH_2$$

#### Formula IV

by refluxing in C<sub>1</sub>-C<sub>4</sub> aliphatic alkanol in the presence or absence of a strong base such as KOH (EP Patent No 21121 and US Patents Nos 4602017 and 4847249).

The Schiff's base of the formula IV may be prepared by a sequence of steps comprising:

(1) reaction of 2,3-dichloroiodobenzene of the formula V:

Formula V

10

15

20

25

with magnesium, followed by reaction of the resulting Grignard moeity with solid carbondioxide;

(2) reaction of the resulting 2,3-dichlorobenzoic acid of the formula VI:

Formula VI

with thionyl chloride in an inert atmosphere such as moisture free nitrogen gas;

(3) reaction of the resulting 2,3-dichlorobenzoyl chloride of the formula VII:

Formula VII

with a metal cyanide and alkali metal iodide such as Cu(one)CN and KI in the presence of an organic solvent such as xylene in an inert atmosphere such as nitrogen; and

(4) reaction of the resulting 2,3-dichlorobenzoylcyanide of the formula VIII:

#### Formula VIII

with aminoguanidine bicarbonate in an organic solvent such as DMSO in aqueous acidic medium using 8N HNO<sub>3</sub>. The purification of crude lamotrigine of the formula I thus obtained by cyclisation of the Schiff's base of the formula IV is carried out by recrystallisation from isopropanol (EP Patents Nos 59987 and 21121 and US Patents Nos 4602017 and 3637688).

The formation of 2,3-dichlorobenzoic acid of the formula VI for the preparation of the Schiff's base of the formula IV by the above route demands a dry environment thereby making the process laborious. These reactions leading to the Schiff's base of the formula IV also employ expensive and hazardous reagents like DMSO in large quantities and xylene. The conversion of 2,3-dichlorobenzoyl chloride to 2,3-dichlorobenzoyl cyanide takes 96 hours thereby making the entire process for the synthesis of the Schiff's base from 2,3-dichlorobenzoyl chloride time consuming (~ 7.5 - 10 days). This route also produces low yields of lamotrigine (~  $\Delta$ 0 %). Therefore this process for the preparation of lamotrigine is not feasible for industrial scale manufacture.

5

10

15

WO 01/49669 PCT/IN00/00001

6

The Schiff's base of the formula IV may also be prepared by the reaction of 2,3-dichlorobenzoyl cyanide of the formula VIII with aminoguanidine bicarbonate in the presence of acetonitrile and dilute aqueous sulfuric acid (US Patent No 4847249). This route for the synthesis of the Schiff's base is reported to produce low yields of lamotrigine.

As lamotrigine has emerged to be one of the promising antiepileptic and anti-convulsant agents for treating CNS disorders, its commercial production assumes significance. Despite the several routes known for the synthesis of lamotrigine there is still need for a route which is safe, convenient, efficient, economical and less time consuming.

#### Disclosure of the invention

An object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I, commonly known as lamotrigine, which is safe and convenient.

Another object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I, commonly known as lamotrigine, which is less time consuming.

5

10

15

Another object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I commonly known as lamotrigine, which is efficient and economical.

5

Another object of the invention is to provide a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine of the formula I, commonly known as lamotrigine, which is suitable for industrial scale manufacture.

10

According to the invention, there is provided a process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I:

15

20

Formula I

commonly known as lamotrigine which comprises:

a) reduction of 2,3-dichloronitrobenzene of the formula IX:

10

15

20

25

8

Formula IX

in  $C_1$ - $C_6$  aliphatic alkanol with hydrogen gas at a pressure of 55-90 psi in the presence of a metal catalyst at 27 - 35°C;

b) diazotisation of the resulting 2,3-dichloroaniline of the formula X:

Formula X

with sodium nitrite and a mineral acid at -5° to 5°C followed by cyano-dediazonation with a metal cyanide at 65 - 80°C;

c) hydrolysis of the resulting 2,3-dichlorobenzonitrile of the formula XI:

Formula XI

under acidic or alkaline conditions;

15

20

d) chlorination of the resulting 2,3-dichlorobenzoic acid of the formula VI:

Formula VI

with a chlorinating agent at 55 - 130°C;

e) cyano-de-halogenation of the resulting 2,3-dichlorobenzoyl chloride of the formula VII:

Formula VII

with a metal cyanide in the presence of an alkali metal iodide by refluxing in an aprotic solvent under an inert atmosphere;

f) condensation of the resulting 2,3-dichlorobenzoyl cyanide of the formula VIII:

Formula VIII

10

15

20

25

with aminoguanidine bicarbonate in an organic solvent in acidic conditions in the presence of a catalyst at 90° - 125°C followed by insitu cyclisation of the resulting Schiff's base of the formula IV:

$$C = N - N - C$$

$$NH_{2}$$

$$NH_{2}$$

Formula IV

by refluxing in an aliphatic alkanol in the presence of a base, and

g) purification of the resulting crude lamotrigine of the formula I:

Formula I

by a known method such as recrystallisation from an aliphatic alkanol or chromatographic separation.

The reduction of 2,3-dichloronitrobenzene may be carried out by dissolution of 2,3-dichloronitrobenzene preferably in methanol. The pressure of the hydrogen gas for reduction may be preferably 50-70psi, still preferably 80 psi and the temperature for the reduction may be preferably 30°C. The metal catalysts used in the reduction reaction may be

3DOCID: <WO 0149669A1 Lo

WO 01/49669 PCT/IN00/00001

11

nickel, Raney nickel, platinum oxide, rhodium-platinum oxide, palladium-carbon, or palladium salts, preferably Raney nickel. An alkali or alkaline earth metal hydroxide such as NaOH, KOH, Ca(OH)<sub>2</sub> or Mg(OH)<sub>2</sub> may be optionally used in the reduction reaction.

5

For the diazotisation of 2,3-dichloroaniline, mineral acids such as HCl or H<sub>2</sub>SO<sub>4</sub>, preferably H<sub>2</sub>SO<sub>4</sub>, may be used. The diazotisation may be carried out preferably at 0°C. The excess sodium nitrite may be optionally decomposed using agents such as urea, sulfamic acid or a small amount of a primary amine dissolved in acid.

10

The cyano-de-diazonation reaction may be carried out using metal cyanides such as NaCN, KCN or Cu(one)CN or a mixture thereof. Preferably a mixture of Cu(one)CN and NaCN may be used. The cyano-de-diazonation may be carried out preferably at 65°C. Excess of cyanide may be optionally decomposed using sodium hypochlorite solution. A phase transfer catalyst such as crown ether or a quaternary ammonium salt in the presence of a nickel catalyst may be optionally used during the cyano-de-diazonation reaction.

20

25

15

The alkaline hydrolysis of 2,3-dichlorobenzonitrile may be carried out using NaOH or KOH in the presence of an aliphatic alkanol such as methanol or ethanol. Preferably methanolic NaOH at reflux temperatures may be used. The unreacted cyano compound may be extracted using toluene, ethyl acetate or a mixture of toluene and ethyl

10

15

acetate, preferably toluene. Mineral acids such as H<sub>2</sub>SO<sub>4</sub> or HCl may be used for acidic hydrolysis.

2,3-dichlorobenzoic acid may be chlorinated using SOCl<sub>2</sub> PCl<sub>3</sub> or PCl<sub>5</sub>. Preferably SOCl<sub>2</sub> at 80°C is used.

The cyano-de-halogenation reaction of 2,3-dichlorobenzoyl chloride is carried out under an inert atmosphere such as nitrogen atmosphere. The metal cyanide used may be Cu(one)CN, NaCN, KCN or a nuxture of Cu(one)CN and NaCN. The alkali metal iodide may be NaI or KI. Preferably Cu(one)CN in the presence of KI may be used. The aprotic solvent for the reaction may be monochlorobenzene, xylene or any other aprotic solvent, preferably monochlorobenzene.

The condensation of 2,3-dichlorobenzoyl cyanide with aminoguanidine bicarbonate is carried out in the presence of a catalyst such as p-toluenesulfonic acid or a lewis acid catalyst such as AlCl<sub>3</sub>, TiCl<sub>4</sub>, FeCl<sub>3</sub>, ZnCl<sub>2</sub>, ZrCl<sub>4</sub> or any protonated acid such as HCl or H<sub>2</sub>SO<sub>4</sub>, in an organic solvent such as toluene or ethyl benzene, in acidic medium using HCl, HNO<sub>3</sub> or H<sub>2</sub>SO<sub>4</sub>. Preferably toluene and H<sub>2</sub>SO<sub>4</sub> with p-toluenesulfonic acid at 100 - 120°C may be used. Insitu cyclisation of the Schiff's base may be carried out in an aliphatic alkanol such as methanol with a strong base such as NaOH, KOH or NaOMe. Preferably methanol and NaOMe may be used.

WO 01/49669

PCT/IN00/00001

For the recrystallisation of the crude lamotrigine, an aliphatic alkanol such as isopropanol, ethanol or methanol, preferably methanol may be used.

5

Pharmaceutically acceptable acid addition salts of lamotrigine of the formula I may be prepared by treating lamotrigine of the formula I with acids such as hydrochloric, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methane sulphonic, p-toluenesulphonic or benzenesulphonic acid.

10

15

20

25

According to the invention a new route is employed in the preparation of lamotrigine of the formula I. The substrate for the preparation thereof viz 2,3-dichloronitrobenzene and also the other reagents of the process of the invention are safe, inexpensive and easily available, thus eliminating the use of hazardous and expensive reagents reported in the prior art. The reactions leading to 2,3-dichlorobenzoic acid need not be carried out in a dry environment. Also chlorination of 2,3-dichlorobenzoic acid is conveniently carried out in a non-inert atmosphere without affecting the efficiency of the process. The use of catalyst during reduction of 2,3-dichloronitrobenzene at room temperature proceeds without dehalogenation thereby giving increased yield and purity of 2,3-Also the other intermediates of the process of the dichloroaniline. invention are obtained in good yields and purity. The conversion of 2,3dichlorobenzoyl chloride to 2,3-dichlorobenzoyl cyanide requires about 6 hours, as against 96 hours reported in a process of the prior art. Similarly the preparation of the Schiff's base from 2,3-dichlorobenzoyl chloride and

10

15

20

25

further insitu cyclisation of the Schiff's base to lamotrigine also is less time consuming (8 hrs), as against 7.5-10 days reported in the prior art processes to prepare the Schiff's base itself. Therefore, the process of the invention is less time consuming and economical. The process of the invention gives a yield of 23% of lamotrigine (starting from 2,3-dichloronitrobenzene) as against a meagre yield of 10% (from 2,3-dichloroiodobenzene) reported in the prior art. Lamotrigine by our invention is also obtained with an excellent purity of 99.67% (by HPLC) after recrystallisation. The process of the invention is, therefore, efficient and economical and also suitable for industrial scale manufacture.

The following experimental example is illustrative of the invention but not limitative of the scope thereof.

Example 1

Preparation of 2,3-dichloroaniline (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>NH<sub>2</sub>):

2,3-Dichloronitrobenzene (800g, 4.17 moles) was dissolved in methanol (5.6L) and charged into an autoclave. Raney nickel (80g, 10% w/w) was added to the solution. The reaction mixture was hydrogenated at 80 psi for 3.5 hrs at 30°C and filtered through celite. Methanol was distilled off to give 2,3-dichloroaniline (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>NH<sub>2</sub>).

Yield = 656 g

WO 01/49669 PCT/IN00/00001

15

Purity = 98% (when analysed by Gas Chromatography)

### Preparation of 2,3-dichlorobenzonitrile (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>CN):

Conc. H<sub>2</sub>SO<sub>4</sub> (1.365 L) and water (4.5 L) were charged into a suitable round bottom flask and the solution was cooled to 0°C. 2,3-Dichloroaniline (650g, 4.012 moles) was added to the above solution and the reaction mixture was cooled and maintained at 0°C. A saturated solution of sodium nitrite (332.22g, 4.815 moles) was added dropwise to the reaction while maintaining the temperature below 5°C. The reaction mixture was stirred at 0-5°C for 1 hr and neutralised with sodium hydroxide at 0 - 5°C. The neutral solution was added dropwise to the cyanide solution [Cyanide solution obtained by mixing Cu(one)CN (365 g. 4.10 moles), NaCN (340 g, 6.93 moles) and water (1.0 L)] at 65°C, under vigorous stirring for a period of 15 mins. The reaction mixture was warmed to 70°C and stirred for another 15 mins. The 2.3dichlorobenzonitrile so formed was extracted using ethylacetate (2.0 L). The organic layer was dried over sodium sulfate and stripped to give a semi-solid mass of 2,3-dichlorobenzonitrile (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>CN).

Yield = 650g

Purity = 92% (when analysed by Gas

Chromatography).

5

10

15

10

15

20

25

## Preparation of 2,3-dichlorobenzoic acid (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COOH):

Sodium hydroxide (168.0g, 4.2 moles, 1.2 eq) was dissolved in a mixture containing methanol (1.08 L) and water (600 ml) maintained at 5-10°C. This solution was then added to a flask containing 2,3-dichlorobenzonitrile (602.0g, 3.5 moles). The reaction mixture was heated and refluxed for 10 hrs with slow stream of air bubbles being purged into the reaction mixture. Methanol was distilled off and water (1.0L) was added to the reaction mixture. The reaction mixture was extracted with toluene (2 x 500ml). The toluene fraction containing unreacted cyano compound was concentrated and recycled. The aqueous portion was treated with conc. HCl (32%, 800 ml) to obtain a white solid precipitate of 2,3-dichlorobenzoic acid(C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COOH) which was filtered and dried.

Yield = 500g

Purity = 97% (when analysed by High Performance Liquid Chromatography)

### Preparation of 2,3-dichlorobenzoyl chloride (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COCl):

2,3-Dichlorobenzoic acid (500g, 2.618 moles) was charged into a 2L four necked round bottom flask containing thionyl chloride (623g, 5.235 moles) and heated at 80°C for 1.0 hr to give 2,3-dichlorobenzoyl chloride (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COCl), after removal of excess of thionyl chloride.

WO 01/49669 PCT/IN00/00001

17

Yield = 500 g

5

10

20

25

Purity = 98% (when analysed by Gas Chromatography)

### Preparation of 2,3-dichlorobenzoyl cyanide (C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COCN):

Copper cyanide (215g, 2.4 moles), potassium iodide (199g, 1.2 moles) and monochlorobenzene (1.0L) were added to a 3L four necked round bottom flask containing 2,3-dichlorobenzoyl chloride (500g, 2.392 moles). The reaction mixture was heated to reflux under nitrogen blanket and maintained at 132-135°C for 6 hrs. The reaction mixture was then filtered and monochlorobenzene distilled off to obtain 2,3-dichlorobenzoyl cyanide(C<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>COCN).

Yield = 470g

Purity = 97% (when analysed by Gas Chromatography)

Preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub>):

Aminoguanidine bicarbonate (136g, 1.0 mole) and toluene (1L) were charged into a 3L four necked round bottom flask. To this slurry was added conc sulfuric acid (98g, 1.0 mole) in a slow stream and p-toluene sulfonic acid (25g). The mixture was stirred for 15 mins and heated to 110°C. Water was azeotroped out from the mixture and the reaction

mixture was cooled to 80°C. To this, 2,3-dichlorobenzoyl cyanide (100g, 0.5 mole) was added and the reaction mixture was refluxed for 3.5 hrs. Toluene was removed completely and the reaction mixture was cooled to 25°C. To it was added sodium methoxide (500 g) (solution in methanol 25% w/w) and refluxed for 3 hrs. Methanol was removed completely and the reaction mixture was cooled to 20°C. Water (400 ml) was added to the reaction mixture and stirred at 20-25°C for 1 hr. The precipitated solid was filtered and washed with water till free of base to give crude 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine (C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub>).

10

5

Yield = 72g

Purity = 94% (when analysed by High Performance Liquid Chromatography)

15

20

The crude product was recrystallised from methanol to give pure 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine(C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub>).

Yield = 64 g

Purity = 99.7% (when analysed by High Performance Liquid Chromatography).

### **CLAIMS**

1) A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine -3,5-diamine of the formula I:

10

5

### Formula I

commonly known as lamotrigine which comprises:

a) reduction of 2,3-dichloronitrobenzene of the formula IX:

15

### Formula IX

- in C<sub>1</sub>-C<sub>6</sub> aliphatic alkanol with hydrogen gas at a pressure of 55-90 psi in the presence of a metal catalyst at 27 35°C;
  - b) diazotisation of the resulting 2,3-dichloroaniline of the formula X:

10

15

20

Formula X

with sodium nitrite and a mineral acid at -5° to 5°C followed by cyano-dediazonation with a metal cyanide at 65 - 80°C;

c) hydrolysis of the resulting 2,3-dichlorobenzonitrile of the formula XI:

Formula XI

under acidic or alkaline conditions;

d) chlorination of the resulting 2,3-dichlorobenzoic acid of the formula VI:

Formula VI

with a chlorinating agent at 55 - 130°C;

10

15

20

25

e) cyano-de-halogenation of the resulting 2,3-dichlorobenzoyl chloride of the formula VII:

### Formula VII

with a metal cyanide in the presence of an alkali metal iodide by refluxing in an aprotic solvent under an inert atmosphere;

f) condensation of the resulting 2,3-dichlorobenzoyl cyanide of the formula VIII:

#### Formula VIII

with aminoguanidine bicarbonate in an organic solvent in acidic conditions in the presence of a catalyst at 90° - 125°C followed by insitu cyclisation of the resulting Schiff's base of the formula IV:

Formula IV

by refluxing in an aliphatic alkanol in the presence of a base; and

10

15

20

25

g) purification of the resulting crude lamotrigine of the formula I:

Formula I

by a known method such as recrystallisation from an aliphatic alkanol or chromatographic separation.

- 2) A process as claimed in claim 1 wherein the reduction of 2,3-dichloronitrobenzene is carried out in methanol using hydrogen gas at a pressure of 80 psi in the presence of Raney nickel at 30°C.
- 3) A process as claimed in claims 1 or 2, wherein the diazotisation of 2,3-dichloroaniline is carried out using sodium nitrite and  $H_2SO_4$  at 0°C.
- 4) A process as claimed in any one of claims 1 to 3, wherein the cyano-de-diazonation is carried out using a mixture of Cu(one)CN and NaCN at 65°C.
- 5) A process as claimed in any one of claims 1 to 4, wherein the hydrolysis of 2,3-dichlorobenzonitrile is carried out by refluxing with methanolic NaOH.

- 6) A process as claimed in any one of claims 1 to 5, wherein chlorination of 2,3-dichlorobenzoic acid is carried out with SOCl<sub>2</sub> at 80°C.
- 7) A process as claimed in any one of claims 1 to 6, wherein the cyano-de-halogenation of 2,3-dichlorobenzoyl chloride is carried out with Cu(one)CN and KI in monochlorobenzene under nitrogen atmosphere at 132-135°C.
- 10 8) A process as claimed in any one of claims 1 to 7, wherein 2,3-dichlorobenzoyl cyanide is condensed with aminoguanidine bicarbonate in toluene in the presence of sulfuric acid and p-toluene sulfonic acid at 100 120°C.
  - 9) A process as claimed in any one of claims 1 to 8, wherein insitu cyclisation of the schiff's base is carried out in methanol in the presence of NaOMe.
- 10) A process as claimed in any one of claims 1 to 9, wherein crude lamotrigine is purified by recrystallisation from methanol.

International application No. PCT/IN 00/0001

### CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup>: C07D 253/07

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

#### REGISTRY, CA, CONSIDERED, EPODOC

C.	DOCUMENTS	CONSIDERED	TO BE RELEVANT
----	-----------	------------	----------------

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Α	EP 963980 A2 (The Wellcome Foundation Limited, UK) 15 December 1999 (15.12.99); reaction scheme p.7, steps b,c,d,e; page 8, lines 1-23.	1-10
Α	WO 9620934 A1 (Wellcome Foundation Limited, UK) 11 July 1996 (11.07.96); example 6; cited in the application.	1-10
А	WO 9620935 A1 (Wellcome Foundation Limited, UK) 11 July 1996 (11.07.96); claims 1-6; cited in the application.	1-10
Α	EP 247892 A1 (Wellcome Foundation Ltd., UK) 2 December 1987 (02.12.87), & US 4847249 A; examples 1.2; cited in the application.	1-10
А	EP 142306 A2 (Wellcome Foundation Ltd., UK) 22 May 1985 (22.05.85); example 1.	1-10
A	US 4486354 A (Wellcome Foundation Ltd., UK) 4 December 1984 (04.12.84), & US 4602017 A; example 1	1-10
	·	

Further documents are listed in the continuation of Box C.	See patent family annex.
Special categories of cited documents:  "A" document defining the general state of the art which is not considered to be of particular relevance  "E" earlier application or patent but published on or after the international filing date  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	"T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
13 September 2000 (13.09.2000)	19 December 2000 (19.12.2000)
Name and mailing adress of the ISA/AT Austrian Patent Office Kohlmarkt 8-10; A-1014 Vienna Facsimile No. 1/53424/535	Authorized officer  MÜLLER-HIEL
Facsimile No. 1/33424/333	Telephone No. 1/53424/434



International application No.

PCT/IN 00/00001

C (Continu		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
А	CA 1119592 A1 (Lilly, Eli, and Co., USA) 9 March 1982 (09.03.82); Compound RN 608-27-5 (diazotization and reaction of, with cyanide).	1-10
A	CA 1119592 A1 (Lilly, Eli, and Co., USA) 9 March 1982 (09.03.82); Compound RN 608-27-5 (diazotization and reaction of, with cyanide).  EP 325892 A2 (Ciba-Geigy AG., Switz.) 2 Augsut 1989 (02.08.89); Compound RN 608-27-5, 3-Amino-1,2-dichlorobenzene(manuf. of, by hydrogenation of dichloronitrobenzene).	1-10



Information on patent family members

International application No. PCTIN 00/00001

		document cited search report	Publication date		Patent f		Publication date
ΕP	A2	963980	15-12-1999	AP	AC	9901481	31-03-1999
ΞP	A3	963980	31-05-2000	ÜĄ	Ã1	20319/99	06-01-2000
				3R	ā.	9900984	02-05-2000
				CN GB	УО У	1238454 9812413	15-12-1999
				UH	OA	9900592	05-06-1998 28-04-1999
				RU	AB	9900592	28-04-2000
				JP	B2	2989189	13-12-1999
				JР	93	00009714	14-01-2000
				Ю	0A	991151	10-03-1999
				МО	A	991151	13-12-1999
WO -	Āl	9620934	i1-07-199€	PL AU	Al Al	331870 43115/96	20-12-1999
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	.1 5. 1950	ΞP	Al	800520	24-07-1996 15-10-1997
				FI	A0	972719	24-06-1997
				FI	A	972719	27-08-1997
				GB	AC	9426447	01-03-1995
				нU	F2	77346	30-03-1996
				Ĵ₽	Т2	11501007	26-01-1999
			,	US	A	5912345	15-06-1999
WO	A1	9620935	13.07.1006	GB	Λ0	9426439	01-03-1995
WO	AI	9020933	11-07-1996	AU EP	A1	43116/96	24-07-1996
				FI	A1 A0	800521 972720	15-10-1997
				FI	A.	972720	24-06-1997 27-08-1997
				GB	A0	9426448	01-03-1995
				HU	A2	77347	30-03-1998
				JP	T2	11507011	22-06-1999
	_			US	A	5925755	20-07-1999
ΞF	Al	247892	02-12-1987	AT	Ε	62902	15-05-1991
E.5	61	247892	24-04-1991	AU	Al	73684/67	03-12-1987
				AU	52	597982	14-06-1990
				CA	A1	1286670	23-07-1991
				DE DK	C0 A0	3769516	29-05-1991
				DK	A O	2759/87 2759/87	29-05-1987 01-12-1987
				DK	Б	166278	29-03-1993
				DK	č	166273	23-08-1993
				FI	A0	872406	29-05-1987
				FI	Α	872406	01-12-1987
				FI	В	90770	15-12-1993
				FI	C	90770	25-03-1994
				GB	AO	8613183	02-07-1986
				GR HU	T3 A2	3001942 45978	23-11-1992 28-09-1988
				HU	B	196769	30-01-1989
				IE	<u> </u>	60626	27-07-1994
				IL	A0	82710	30-11-1987
				IL	Al	82710	15-01-1992
				JP	A2	62289570	16-12-1987
				JP	B4	7051571	05-06-1995
			•	KR	В1	9102254	08-04-1991
				NZ US	A A	220497 4847249	28-05-1990
				ZA	A	8703896	11-07-1989 25-01-1989
EP	A2	142306	22-05-1985	AU	A1	34758/94	09-05-1985
EP	A3	142306	20-11-1986	AU	B2	564667	20-08-1987
				CA	Λl	1261328	26-09-1989
				DD	A5	224033	26-06-1985
				DK	A0	5121/84	26-10-1984
				DK	Α	5121/84	28-04-1985
				ES	Al	537104	16-04-1986
				ES ES	A5	537104 8606304	16-05-1986
	•			ES FI	A 1 A 0	8606304 844212	01-10-1986 26-10-1984
				FI	A	844212	28-04-1984
				GB	Ã0	8328757	30-11-1983
				GR	A	80723	07-02-1985
				HU	Λ2	36102	28-08-1985
				нυ	В	191566	30-03-1987
				.11	ΑÜ	73332	31-01-1985
				1 L	AΙ	73332	30-06-1988
				JP	A2	60109577 8900991	15-06-1985
						a unitiuu t	
				KR MC	.B1 ∧	1628	15-04-1989 26-09-1985



Information on patent family members

International application No. PCTIN 00/00001

	Patent document cited in search report	Publication date		Patent memb	family per(s)	Publication date
			NZ PH	A A	210000	31-08-1987
			PL	Α 1	21926 250213	08-04-1988 03-12-1985
			PL	13	144899	30-07-1988
1			PT	Α	79416	01-11-1984
1			PT	В	79416	13-11-1986
			នប	A.3	1371500	30-01-1988
İ			US	A	4649139	10-03-1987
	US A 4486354	24 12 1004	2A	P.	8408388	25-06-1986
1	05 A 4486354	04-12-1984	AR	A1	227521	15-11-1982
			TA AT	A B	2896/80 370097	15-07-1982
1			AU	A1	58906/80	25-02-1983 04-12-1980
1			ΑU	E2	530999	04-08-1983
			ВG	В2	60427	31-03-1995
1			Cν	Al	1112643	17-11-1981
}			CA	A2	1133938	19-10-1982
			cs	B2	234018	14-03-1985
			C2	A3	9103848	13-10-1993
			DD DE	C 0	151309 3063084	14-10-1981
1			DE	CO	3071000	16-06-1983 19-09-1985
			DK	A	2338/80	02-12-1980
]			DK	В	153787	05-09-1988
			DK	С	153787	16-01-1989
Ī			EP	Αl	21121	07-01-1981
			EP	Al	59987	15-09-1982
1			EP	B1	21121	11-05-1983
]			EP	В1	59987	14-08-1985
			ES ES	A1 A5	491998 491998	16-05-1981
			ES	A1	6104993	15-06-1981 01-08-1981
			FI	Α	801758	02-12-1980
1			FI	A	840888	06-03-1984
i			FI	ΑO	640888	06-03-1984
			FI	В	67844	28-02-1985
			FI	С	67844	10-06-1985
1			FI	В	73203	29-05-1987
			FI GR	C A	73203 68360	10-09-1987
1			HU	8	182086	28-12-1981 28-12-1983
			IE	B	49823	25-12-1985
1			IL	A0	60201	31-07-1980
1			I L	A1	60201	31-05-1984
			ΙT	AO	8048648	30-05-1980
1			IT	A	1147087	19-11-1986
			JP	A2	56025169	10-03-1981
			JP JP	A2 B4	61033163 1044179	17-02-1986
			JP	B4	1044706	26-09-1989 29-09-1989
			LT	A3	2066	15-06-1993
			MY	Α	62/85	31-12-1985
			NZ	Α	193890	06-07-1984
			NZ	A	198159	09-11-1984
ļ			PL	Al	224633	13-02-1981
1			PL	B1	124029	31-12-1982
			SU US	A 3 A	1055331 4602017	15-11-1983
i			YU	Â	1456/80	22-07-1986 28-02-1983
			ZA	A	8003250	27-01-1982
ĺ			ZW	A	129/80	06-01-1982
1	CA Al 1119592	09-03-1982	AR	λl	218496	13-06-1980
1			AR	Al	222829	30-06-1981
l			BE	A1	868471	27-12-1978
1			CA	A2	1122528	27-04-1962
			CH CH	A A	641165 641677	15-02-1984
			DE	A Al	2827931	15-03-1984 18-01-1979
			DE	. 62	2827931	11-11-1982
1			FR	ΥJ	2395997	26-01-1979
			FR	В1	2395997	26-06-1981
			GB	V.	1603947	02-12-1981
ĺ			но	P	177824	28-12-1981
			ΙE	В	47057	14-12-1983
T .			ΙL	ΑO	55002	31-08-1978



Information on patent family members

International application No. PCTIN 00/00001

Publication date	Patent family member(s)		Publication date	document cited search report			
	55002	A1	IL				
30-06-197	7825254	λO	iΤ				
07-09-198	1098353	A	IΤ				
03-02-197	54014993	A.2	JP				
27-12-198	59053911	84	JP				
03-01-197	7807002	A	NL				
30-06-199	1304412	Al	CA	02-08-1989	325892	A2	EF
19-03-199	3878218	C0	DE	05-09-1990	325892	A3	F:P
05-01-199	2000740	A2	JP	03-02-1993	325892	21	E.P
24-12-199	2694154	B2	JP				
02-10-199	4960936	A	US				

# THIS PAGE BLANK (05210